Literature DB >> 1693529

Identification and characterization of a new surface membrane antigen found predominantly on malignant B lymphocytes.

R D Gingrich1, C E Dahle, K F Hoskins, M J Senneff.   

Abstract

A monoclonal antibody, 1D10, was derived that identifies a new antigenic epitope on the surface of malignant B lymphocytes. Normal resting and stimulated lymphocytes do not express the antigen. The majority of individuals with acute Epstein-Barr virus infection express the antigen on their lymphocytes, and in these patients, the T lymphocyte may also be antigen positive. The antigen was found on B-lymphoid neoplasia from the early pre-B cell stage through terminally differentiated plasma cells, a characteristic not reported for other B cell-associated antigens. Studies on homozygous typing cells and cells from individuals with known HLA phenotypes indicate that the antigen does not segregate in a pattern characteristic for major histocompatibility antigens. The molecule is a heterodimeric polypeptide with the molecular weight and isoelectric points of the alpha and beta chains being 32,000 d/4 and 28,000 d/6, respectively. Evidence is presented that the 1D10 molecule is not HLA-DR, -DP, or -DQ. By extrapolation, we suggest that this novel molecule may represent HLA D-region gene expression of a gene(s) not normally expressed. Potential candidates are D-region pseudogenes. We conclude that the antigenic epitope identified by the 1D10 monoclonal antibody is unique among previously described B-lymphocyte antigens. Further studies of the factors controlling the expression of this molecule, as well as studies designed to look at the possible cellular function, may provide insights for understanding crucial events in the malignant transformation of lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1693529

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  7 in total

Review 1.  Investigational immunotherapeutics for B-cell malignancies.

Authors:  Alfonso Quintás-Cardama; William Wierda; Susan O'Brien
Journal:  J Clin Oncol       Date:  2010-01-04       Impact factor: 44.544

2.  Combating non-Hodgkin lymphoma by targeting both CD20 and HLA-DR through CD20-243 CrossMab.

Authors:  Lei Zhao; Feiyue Xie; Xin Tong; Huafei Li; Yaling Chen; Weizhu Qian; Shuyan Duan; Juan Zheng; Ziye Zhao; Bohua Li; Dapeng Zhang; Jian Zhao; Jianxin Dai; Hao Wang; Sheng Hou; Yajun Guo
Journal:  MAbs       Date:  2014-03-26       Impact factor: 5.857

3.  A Phase I Study of Apolizumab, an Anti-HLA-DR ß-chain Monoclonal Antibody, in Patients With Solid Tumor Malignancies.

Authors:  Paula M Fracasso; Sherry A Goodner; Jonathan D Wildi; Michael J Naughton; Gerald P Linette; Ramaswamy Govindan; Benjamin R Tan; Kristie A Blum; Gary J Jones; Tillman E Pearce; Daniel J Levitt; Gerald H Clamon
Journal:  Am J Clin Oncol       Date:  2022-06-01       Impact factor: 2.787

4.  Rapidly progressive sacroiliitis in a patient with lymphocytic lymphoma.

Authors:  M R Cohen; G E Carrera; J Lundberg
Journal:  Ann Rheum Dis       Date:  1993-03       Impact factor: 19.103

Review 5.  Antibody therapy for chronic lymphocytic leukemia.

Authors:  Beth A Christian; Thomas S Lin
Journal:  Semin Hematol       Date:  2008-04       Impact factor: 3.851

6.  A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia.

Authors:  Thomas S Lin; Wendy Stock; Huiping Xu; Mitch A Phelps; Margaret S Lucas; Sara K Guster; Bruce R Briggs; Carolyn Cheney; Pierluigi Porcu; Ian W Flinn; Michael R Grever; James T Dalton; John C Byrd
Journal:  Leuk Lymphoma       Date:  2009-12

7.  Synthesis and evaluation of 99mTc-labelled monoclonal antibody 1D09C3 for molecular imaging of major histocompatibility complex class II protein expression.

Authors:  Gaurav Malviya; E F J de Vries; Rudi A Dierckx; Alberto Signore
Journal:  Mol Imaging Biol       Date:  2011-10       Impact factor: 3.488

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.